Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Nrf2-mediated metabolic reprogramming drives regulatory T cell accumulation in hepatocellular carcinoma.

Nature communications·2026

Same author

Genetic risk in extremely early onset type 1 diabetes.

medRxiv : the preprint server for health sciences·2025

Same author

Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency.

The Journal of experimental medicine·2024

Same author

The Impact of Immune-Modifying Treatments for Skin Diseases on the Immune Response to COVID-19 Vaccines: a Narrative Review.

Current dermatology reports·2022

Same author

Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes.

Diabetes·2022

Same author

Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol.

BMJ open·2021

Search research articles

Related Experiment Video

Updated: Aug 20, 2025

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

IL-2-based approaches to Treg enhancement.

Ffion Harris¹, Yoana Arroyo Berdugo¹, Timothy Tree^1,2

¹Department of Immunobiology, Faculty of Life Sciences and Medicine, King's College, London, UK.

Clinical and Experimental Immunology

|November 18, 2022

Summary

Regulatory T cells (Tregs) are crucial for immune balance but are often defective in autoimmune diseases. Low-dose interleukin-2 (IL-2) and engineered IL-2 therapies show promise for treating these conditions.

Keywords:

autoimmunity autoinflammatory disease cytokines immunotherapy regulatory T cells

More Related Videos

In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol

In Vitro Differentiation of Human CD4⁺FOXP3⁺ Induced Regulatory T Cells (iTregs) from Naïve CD4⁺ T Cells Using a TGF-β-containing Protocol

Published on: December 30, 2016

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Related Experiment Videos

Last Updated: Aug 20, 2025

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol

In Vitro Differentiation of Human CD4⁺FOXP3⁺ Induced Regulatory T Cells (iTregs) from Naïve CD4⁺ T Cells Using a TGF-β-containing Protocol

Published on: December 30, 2016

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Area of Science:

Immunology
Autoimmune Diseases
Therapeutic Development

Background:

Immune homeostasis relies on regulatory T cells (Tregs) to suppress immune responses.
Defective Tregs are implicated in common autoimmune diseases.
The interleukin-2 (IL-2) signaling pathway is a key dysregulated mechanism in autoimmunity.

Approach:

This review examines the therapeutic rationale for low-dose IL-2 in autoimmune diseases.
It evaluates current clinical trial outcomes for IL-2-based therapies.
Novel engineered IL-2 variants with enhanced Treg specificity are also discussed.

Key Points:

IL-2 is vital for Treg function and survival.
Tregs are highly sensitive to IL-2 levels.
Gene polymorphisms linked to autoimmunity implicate the IL-2 pathway.

Conclusions:

IL-2 signaling is a vital target for autoimmune disease treatment.
Low-dose and engineered IL-2 therapies represent potential therapeutic strategies.
Further research is needed to establish the efficacy of these IL-2-based treatments in patients.